Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults

Nicholas Beeching; Paul D. Clarke; Nicholas R. Nicholas; Jackie Pirmohamed; Keith Veitch; Françoise Weber

doi:10.1016/j.vaccine.2004.05.040

Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults

Nicholas Beeching, Paul D. Clarke, Nicholas R. Nicholas, Jackie Pirmohamed, Keith Veitch, Françoise Weber

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine. Viatim(TM), and the marketed Hepatyrix(TM) vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim(TM) compared with Hepatyrix(TM). Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim(TM) vaccinees had more mild or moderate local reactions (82.7%) than Hepatyrix(TM) (53.1%, p < 0.001). In this direct comparison Viatim(TM) induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix(TM). (C) 2004 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	29-35
Number of pages	7
Journal	Vaccine
Volume	23
Issue number	1
DOIs	https://doi.org/10.1016/j.vaccine.2004.05.040
Publication status	Published - 15 Nov 2004

Keywords

Combined vaccine
Hepatitis A
Typhoid

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2004.05.040

Cite this

@article{f359e06ccf844b259ec9590715866994,

title = "Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults",

abstract = "A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine. Viatim(TM), and the marketed Hepatyrix(TM) vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim(TM) compared with Hepatyrix(TM). Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim(TM) vaccinees had more mild or moderate local reactions (82.7\%) than Hepatyrix(TM) (53.1\%, p < 0.001). In this direct comparison Viatim(TM) induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix(TM). (C) 2004 Elsevier Ltd. All rights reserved.",

keywords = "Combined vaccine, Hepatitis A, Typhoid",

author = "Nicholas Beeching and Clarke, \{Paul D.\} and Nicholas, \{Nicholas R.\} and Jackie Pirmohamed and Keith Veitch and Fran{\c c}oise Weber",

year = "2004",

month = nov,

day = "15",

doi = "10.1016/j.vaccine.2004.05.040",

language = "English",

volume = "23",

pages = "29--35",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults

AU - Beeching, Nicholas

AU - Clarke, Paul D.

AU - Nicholas, Nicholas R.

AU - Pirmohamed, Jackie

AU - Veitch, Keith

AU - Weber, Françoise

PY - 2004/11/15

Y1 - 2004/11/15

N2 - A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine. Viatim(TM), and the marketed Hepatyrix(TM) vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim(TM) compared with Hepatyrix(TM). Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim(TM) vaccinees had more mild or moderate local reactions (82.7%) than Hepatyrix(TM) (53.1%, p < 0.001). In this direct comparison Viatim(TM) induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix(TM). (C) 2004 Elsevier Ltd. All rights reserved.

AB - A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine. Viatim(TM), and the marketed Hepatyrix(TM) vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim(TM) compared with Hepatyrix(TM). Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim(TM) vaccinees had more mild or moderate local reactions (82.7%) than Hepatyrix(TM) (53.1%, p < 0.001). In this direct comparison Viatim(TM) induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix(TM). (C) 2004 Elsevier Ltd. All rights reserved.

KW - Combined vaccine

KW - Hepatitis A

KW - Typhoid

U2 - 10.1016/j.vaccine.2004.05.040

DO - 10.1016/j.vaccine.2004.05.040

M3 - Article

SN - 0264-410X

VL - 23

SP - 29

EP - 35

JO - Vaccine

JF - Vaccine

IS - 1

ER -

Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this